The purpose of this study is to examine how patients with multiple myeloma (MM) have been impacted by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. The study will use a questionnaire to further understand how patients are being affected and gather information in order to track the long-term effects of the coronavirus. The scope of the questionnaire will include, COVID-19 diagnosis and treatment, changes in myeloma treatment and care, clinical trial familiarity, health and fitness, and quality of life. This questionnaire is a follow-on to the "MM and COVID-19" questionnaire.
Study Type
OBSERVATIONAL
Enrollment
1,500
Series of questions covering COVID-19 diagnosis and treatment, changes in myeloma treatment and care, clinical trial familiarity, health and fitness, and quality of life.
HealthTree.org (Online)
Lehi, Utah, United States
RECRUITINGCOVID-19 Diagnosis and Treatment
Describe how patients diagnosed with COVID-19 were treated for the virus.
Time frame: Up to one year
Changes to Myeloma Treatment and Care
Describe which treatments were changed and how care was affected as a result of COVID-19
Time frame: Up to one year
Health and Fitness
Describe how COVID-19 impacted patient's health and fitness
Time frame: Up to one year
Quality of Life (QOL) Distress Screening tool
Describe how patients rate their level of concern on psychosocial, practical, and physical needs during the COVID-19 pandemic using the Cancer Support Community's CancerSupportSource distress screening tool.
Time frame: Up to one year
Clinical Trial Familiarity
Describe how familiar patients are with multiple myeloma clinical trials.
Time frame: Upon enrollment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.